Supplements > Beyond Charitable Assistance: Sustainable Strategies for Providing Access to Critical Medications
Supplements – Beyond Charitable Assistance: Sustainable Strategies for Providing Access to Critical Medications
March 27, 2017 – Veena Shankaran, MD, MS; Hannah Linden, MD; Jordan Steelquist, BA; Kate Watabayashi, BA; Karma Kreizenbeck, BA; Tony Leahy, JD; and Karen Overstreet, JD
This paper describes results from a patient survey regarding treatment-related financial experiences and interest in a financial literacy course.
Reducing Barriers to Medication Access and Adherence for ACA and Medicaid Participants: A Peer-to-Peer, Community-Based Approach
March 27, 2017 – Andrea Baer, MS, and Marcia Baker, MS Ed
How peer-to-peer, community support programs can educate and empower patients to become more adherent to treatments, which will improve outcomes and reduce healthcare costs.
The Increasing Need for the Safety Net: An Introduction to the Patient Access Network Foundation and AJMC® Collaborative Supplement
March 27, 2017 – Dan Klein, President and CEO, Patient Access Network Foundation
This supplement showcases the winning papers and case studies from the PAN Challenge, which aimed to stimulate a dialogue on ways to reduce or eliminate the barriers and disparities that Medicare and ACA enrollees face in obtaining medications to treat life-threatening, chronic, and rare diseases.
Reducing Out-of-Pocket Cost Barriers to Specialty Drug Use Under Medicare Part D: Addressing the Problem of "Too Much Too Soon"
March 17, 2017 – Jalpa A. Doshi, PhD; Pengxiang Li, PhD; Amy R. Pettit, PhD; J. Samantha Dougherty, PhD; Ashley Flint, MPP; and Vrushabh P. Ladage, BS
Medicare claims analyses offer insight into how proposed policy changes would affect out-of-pocket prescription costs for Part D beneficiaries requiring specialty drugs.
March 27, 2017 – Kai Yeung, PharmD, PhD; Anirban Basu, PhD; Zachary A. Marcum, PharmD, PhD; John B. Watkins, PharmD, MPH, BCPS; and Sean D. Sullivan, PhD
A value-based formulary was implemented that used cost-effectiveness analysis to inform medication co-payments. Diabetes cohort expenditures decreased by $9 per member per month.